Back
Day Range
$86.36
$87.68
52-Week Range
$79.55
$106.33
Volume
6,901,628
50D / 200D Avg
$96.83
/
$94.49
Prev Close
$86.16
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 24.0 | 0.4 |
| P/B | 2.3 | 2.9 |
| ROE % | 9.5 | 3.7 |
| Net Margin % | 13.9 | 3.8 |
| Rev Growth 5Y % | 2.7 | 10.0 |
| D/E | 0.6 | 0.2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 15, 2025 |
Marinaro Michael
EVP, Pres MedSurg and Americas
|
other | 1,371 | $99.87 | $136,922 |
| Dec 15, 2025 |
Wall Brett A.
EVP & Pres Neuroscience
|
other | 439 | $99.87 | $43,843 |
| Dec 15, 2025 |
Martha Geoffrey
Chairman and CEO
|
other | 1,564 | $99.87 | $156,197 |
| Dec 5, 2025 |
KIIL HARRY SKIP
EVP & President Cardiovascular
|
other | 1,702 | $101.36 | $172,515 |
| Nov 20, 2025 |
Blomquist Denise L.
Chief Accounting Officer
|
other | 170 | — | — |
| Nov 19, 2025 |
Smith Gregory L
EVP Global Ops & Supply Chain
|
sell | 30,000 | $101.93 | $3,058,451 |
| Aug 25, 2025 |
Jellison William R
Director
|
buy | 2,500 | $92.37 | $230,925 |
| Aug 22, 2025 |
Jellison William R
Director
|
buy | 2,500 | $92.73 | $231,825 |
| Aug 20, 2025 |
Marinaro Michael
EVP, Pres MedSurg and Americas
|
other | 1,052 | $93.22 | $98,067 |
| Jul 31, 2025 |
Smith Gregory L
EVP Global Ops & Supply Chain
|
other | 1,630 | $90.24 | $147,091 |
| Jun 3, 2025 |
Blomquist Denise L.
Chief Accounting Officer
|
other | 310 | — | — |
| Apr 29, 2025 |
Lofton Kevin E
Director
|
other | 216 | $84.60 | $18,274 |
| Apr 29, 2025 |
Fonseca Lidia
Director
|
other | 216 | $84.60 | $18,274 |
| Apr 29, 2025 |
Powell Kendall J
Director
|
other | 216 | $84.60 | $18,274 |
| Apr 29, 2025 |
HOGAN RANDALL J
Director
|
other | 216 | $84.60 | $18,274 |
| Apr 29, 2025 |
DONNELLY SCOTT C
Director
|
other | 216 | $84.60 | $18,274 |
| Apr 28, 2025 |
Lofton Kevin E
Director
|
grant | 2,083 | $84.04 | $175,055 |
| Apr 28, 2025 |
Fonseca Lidia
Director
|
grant | 2,083 | $84.04 | $175,055 |
| Apr 28, 2025 |
Powell Kendall J
Director
|
grant | 2,083 | $84.04 | $175,055 |
| Apr 28, 2025 |
HOGAN RANDALL J
Director
|
grant | 2,083 | $84.04 | $175,055 |
Key Takeaways
Revenue grew 2.73% annually over 5 years — modest growth
Earnings grew 26.82% over the past year
Generating 5.19B in free cash flow
PEG of 0.75 suggests growth is underpriced
Cash machine — converts 111.22% of earnings into free cash flow
Capital efficient — spends only 5.54% of revenue on capex
Growth
Revenue Growth (5Y)
2.73%
Revenue (1Y)3.62%
Earnings (1Y)26.82%
FCF Growth (3Y)6.40%
Quality
Return on Equity
9.49%
ROIC5.84%
Net Margin13.90%
Op. Margin17.76%
Safety
Debt / Equity
0.59
Current Ratio1.85
Interest Coverage8.17
Valuation
P/E Ratio
24.01
P/B Ratio2.33
EV/EBITDA23.21
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 3.62% | Revenue Growth (3Y) | 3.63% |
| Earnings Growth (1Y) | 26.82% | Earnings Growth (3Y) | 11.38% |
| Revenue Growth (5Y) | 2.73% | Earnings Growth (5Y) | 6.63% |
| Profitability | |||
| Revenue (TTM) | 33.54B | Net Income (TTM) | 4.66B |
| ROE | 9.49% | ROA | 5.09% |
| Gross Margin | 65.32% | Operating Margin | 17.76% |
| Net Margin | 13.90% | Free Cash Flow (TTM) | 5.19B |
| ROIC | 5.84% | FCF Growth (3Y) | 6.40% |
| Safety | |||
| Debt / Equity | 0.59 | Current Ratio | 1.85 |
| Interest Coverage | 8.17 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 24.01 | P/B Ratio | 2.33 |
| P/S Ratio | 3.34 | PEG Ratio | 0.75 |
| EV/EBITDA | 23.21 | Dividend Yield | 0.03% |
| Market Cap | 111.92B | Enterprise Value | 138.21B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 33.54B | 32.36B | 31.23B | 31.69B | 30.12B |
| Net Income | 4.66B | 3.68B | 3.76B | 5.04B | 3.61B |
| EPS (Diluted) | 3.61 | 2.76 | 2.82 | 3.73 | 2.66 |
| Gross Profit | 21.91B | 21.15B | 20.51B | 21.54B | 19.63B |
| Operating Income | 5.96B | 5.14B | 5.49B | 5.75B | 4.48B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 91.68B | 89.98B | 90.95B | 90.98B | 93.08B |
| Total Liabilities | 43.42B | 39.56B | 39.28B | 38.26B | 41.48B |
| Shareholders' Equity | 48.02B | 50.21B | 51.48B | 52.55B | 51.43B |
| Total Debt | 28.52B | 25.02B | 24.36B | 24.11B | 26.39B |
| Cash & Equivalents | 2.22B | 1.28B | 1.54B | 3.71B | 3.59B |
| Current Assets | 23.81B | 21.94B | 21.68B | 23.06B | 22.55B |
| Current Liabilities | 12.88B | 10.79B | 9.05B | 12.39B | 8.51B |